[Application of the saralasin test to the treatment of malignant or accelerated arterial hypertension (author's transl)].
A test using saralasin, an antagonist of angiotensin II, was carried out in 9 patients with malignant or accelerated arterial hypertension, and the initial treatment was modified according to the results: if the fall in mean arterial blood pressure was greater than 10 p. cent, beta-blockers or alpha-beta blockers were prescribed alone; if not, diuretics were used concomitantly. Blood pressure response correlated with plasma renin activity and aldosterone, and the reduction in mean arterial blood pressure after 24 hours' treatment correlated with that observed with saralasin. In longer term saralasin has no predictive value with regard to the course of the hypertensive disease or the results of future treatments.
D000328:Adult; D000804:Angiotensin II / Q000031:analogs & derivatives*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006974:Hypertension, Malignant / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D012504:Saralasin; D013997:Time Factors
D000804:Angiotensin II; D012504:Saralasin
Test à la saralasine: intérêt dans le traitement des hypertensions sévères.